GlassScriptPhysician profile
Katherine Rose Mcdaniel
NPI 1831623131
$8,402.27
in general payments reported to CMS, 2019-2025
53 companies · $1,300 in 2025
The $1,300 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.84 · 2020: $268 · 2021: $1,279 · 2022: $1,855 · 2023: $1,813 · 2024: $1,838 · 2025: $1,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,951.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,775.56 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,134.34 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $952.69 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $541.33 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $493.26 | 2022-2025 | |
| Amgen INC. | $326.18 | 2020-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.39 | 2021-2024 | Jardiance, Synjardy, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $254.10 | 2021-2025 | Xifaxan |
| Amarin Pharma, INC. | $219.30 | 2020-2022 | |
| Glaxosmithkline, LLC. | $206.37 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $141.65 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Biohaven Pharmaceutical Holding Company LTD. | $138.40 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.18 | 2022-2023 | |
| Astellas Pharma US INC | $122.80 | 2023-2025 | Veozah, Myrbetriq |
| Idorsia Pharmaceuticals US INC | $122.66 | 2023-2024 | Quviviq |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.